Q-omics provides the consensus-scored SLX1A-SULT1A3 profile across patient tissues and cancer cell-line models. SLX1A-SULT1A3 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, SLX1A-SULT1A3 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, SLX1A-SULT1A3 RNA expression shows 16,499 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, HNSC, and UVM as cancer lineages where SLX1A-SULT1A3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLX1A-SULT1A3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLX1A-SULT1A3 survival associations across molecular data types. SLX1A-SULT1A3 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLX1A-SULT1A3 RNA expression–survival associations across cancer types. High SLX1A-SULT1A3 expression shows unfavorable associations in KIRP, ACC, PRAD, LIHC, COAD and KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for SLX1A-SULT1A3 RNA expression.
This table summarizes SLX1A-SULT1A3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for SLX1A-SULT1A3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLX1A-SULT1A3 shows higher tumor expression in HNSC, KIRC, BLCA, STAD, KIRP and LUSC. The HNSC box plot shows higher SLX1A-SULT1A3 RNA expression in tumor versus normal tissue (log2 FC = +0.033, t-test p = .002).
This table shows molecular features associated with SLX1A-SULT1A3 in patient tissues and cancer cell lines. In patient samples, SLX1A-SULT1A3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
